Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021


HomeClinical Trials, Studies, Data UpdatesHRS Scientific Sessions: Boston Scientific LBCT

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

Key findings from the studies include:

Data demonstrated that MSP with RESONATE™ X4 CRT-D devices is safe and effective when used in non-responders to conventional CRT, and showed that MSP can convert non-responders to responders with minimal impact to battery life of the CRT-D devices. The study had an initial responder rate to CRT therapy of 74% and exceeded pre-determined performance and safety goals:

o   At 12 months, 78 patients met the effectiveness endpoint analysis requirements and demonstrated a response rate to MSP of 51.3% (40/78), compared to a predefined goal of 5%.

o   A 99% complication free rate compared to a predefined goal of 90%.

FLXibility Post-Approval Study

  • The first patient follow-up visit data from the European FLXibility registry with the next-generation WATCHMAN FLX device demonstrated excellent procedural success rates in everyday clinical practice.

o   This included high effective LAA closure rates (87.6% complete seal, 12.4% residual blood flow size ≤ 5mm) and low short-term complications through 120 days, including 0.7% all-stroke, 1% pericardial effusion, 0.3% device embolization and no cases of systemic embolism.

o   These positive results are similar to those observed in the PINNACLE FLX pivotal approval trial, for which 2 -year results were just announced.

NESTed Post Approval Study

  • Two-year data from the NESTed Post-Approval Study with the WATCHMAN device, stemming from the NCDR LAAO Registry, demonstrated low rates of stroke and systemic embolism.

o   The study met its primary safety endpoint (defined as all-cause death, ischemic stroke, systemic embolism or procedure-related events requiring intervention within 7 days or hospital discharge) with a rate of 1.4%; and second primary efficacy endpoint (defined as 2-year ischemic stroke and systemic embolism) with a rate of 3.0%.

o   The first primary efficacy endpoint (defined as 2-year all-cause death, hemorrhagic stroke, ischemic stroke and systemic embolism) exceeded the performance goal at 17.1%, (PG was <15%), but was driven by non-cardiovascular mortality in this older, high-risk population.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy